AssetMark Inc
RCUS icon

AssetMark Inc’s Arcus Biosciences RCUS Stock Holding History

AssetMark Inc’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$336 Buy
+13
New +$367 ﹤0.01% 3521
2025
Q2 		– Sell
-43
Closed -$338 – 3102
2025
Q1 		$338 Buy
+43
New +$499 ﹤0.01% 2472

Other funds holding RCUS

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

AssetMark Inc's RCUS Position: Q3 2026 in Review

AssetMark Inc opened a new position in Arcus Biosciences (RCUS) in Q3 2026: 13 shares worth $336. The stake represents ﹤0.01% of the portfolio and ranks #3521 among its holdings. This is a return to the name: AssetMark Inc previously reported a position in RCUS as recently as Q1 2025.

AssetMark Inc first reported a position in RCUS in Q1 2025 and has held it in 2 quarters since. The position peaked at $338 in Q1 2025. 63 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • AssetMark Inc held 13 shares of Arcus Biosciences worth $336 as of Q3 2026.
  • Arcus Biosciences was a new AssetMark Inc position in Q3 2026.
  • Arcus Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3521 holding.
  • AssetMark Inc first reported a position in Arcus Biosciences in Q1 2025 and has held it in 2 quarters since.
  • AssetMark Inc's Arcus Biosciences position peaked at $338 in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.